P935: REAL WORLD COMPARATIVE ANALYSIS OF THE EFFICACY OF TECLISTAMAB VERSUS CURRENT TREATMENTS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE LOCOMOTION STUDY

• H. Einsele,
• P. Moreau,
• M. Delforge,
• N. W. van de Donk,
• F. Ghilotti,
• J. Diels,
• A. Elsada,
• V. Strulev,
• L. Pei,
• R. Kobos,
• J. Smit,
• M. Slavcev,
• K. Weisel,
• M.-V. Mateos

Affiliations

H. Einsele

1 Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Wuerzburg, Germany

P. Moreau

2 Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France

M. Delforge

3 University of Leuven, Leuven, Belgium

N. W. van de Donk

4 Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands

F. Ghilotti

5 Janssen-Cilag SpA, Cologno Monzese, United States of America

J. Diels

6 Janssen Pharmaceutica NV, Beerse, Belgium

A. Elsada

7 Janssen-Cilag, High Wycombe, Buckinghamshire, United Kingdom

V. Strulev

6 Janssen Pharmaceutica NV, Beerse, Belgium

L. Pei

8 Janssen Research & Development, Raritan

R. Kobos

8 Janssen Research & Development, Raritan

J. Smit

9 Janssen Research & Development, Spring House

M. Slavcev

10 Janssen Global Services, LLC, Raritan, United States of America

K. Weisel

11 University Medical Center Hamburg-Eppendorf, Hamburg, Germany

M.-V. Mateos

12 University Hospital of Salamanca/IBSAL, CIC, Salamanca, Spain